Nutrien Ltd <NTR.N>: Barclays cuts target price to $78 from $81
NTR•Related News
Mereo BioPharma signs option-and-license deal with Sentynl for US rights to alvelestat in AATD lung disease
MREO•
Viavi EVP and Chief Marketing & Strategy Officer Paul McNab sells 1,595 shares worth $59,593.15
VIAV•
Beachbody publishes investor presentation on BODi turnaround to multi-channel direct-to-consumer model
BODI•
MarineMax Inc <HZO.N>: B. Riley raises target price to $53 from $35
HZO•
Varex Imaging <VREX.O>: Oppenheimer cuts to perform from outperform
VREX•